2023-05-11 17:02:59 ET
- Eiger BioPharmaceuticals press release ( NASDAQ: EIGR ): Q1 GAAP EPS of -$0.52 misses by $0.12 .
- Revenue of $4.1M (+53.6% Y/Y) beats by $0.28M .
-
Cost of sales was flat for the three months ended March 31, 2023 compared to the same period in 2022.
-
Cash, cash equivalents, and short-term debt securities as of March 31, 2023 totaled $75.3 million compared to $98.9 million as of December 31, 2022.
-
As of March 31, 2023, the Company had 44,296,417 common shares outstanding.
-
Financial Guidance
-
$75.3 million in cash, cash equivalents, and short-term debt securities as of March 31, 2023
For further details see:
Eiger BioPharmaceuticals GAAP EPS of -$0.52 misses by $0.12, revenue of $4.1M beats by $0.28M